IngentaConnect Occurrence of Malignancies in Hungarian Patients with Systemic Lu...

Authors: TARR, TÜNDE¹; GYORFY, BALÁZS¹; SZEKANECZ, ÉVA²; BHATTOA, HARJIT PAL³; ZEHER, MARGIT¹; SZEGEDI, GYULA¹; KISS, EMESE¹

Source: Annals of the New York Academy of Sciences, Volume 1108, Number 1, June 2007 , pp. 76-82(7)

Publisher: Blackwell Publishing

Abstract:

As a result of increasing life expectancy of lupus patients, malignant disorders have become major determinants of morbidity and mortality. The objectives of this study were to analyze cancer-associated morbidity and mortality, the type of malignancies in Hungarian lupus patients, and to analyze association with immune-suppressive therapy, disease duration, and age of the patients. Data from 860 systemic lupus erythematosus (SLE) patients were retrospectively analyzed in a study period between 1970 and 2004. Results were compared to data from age- and sex-matched population obtained from the Health for All database, and also to literature data. A total of 37 patients presented with cancer, reflecting 4.3% cancer-associated morbidity. Patients were 47 (20-73) years old at the onset of malignancy, which appeared 13 (1-45) years later than SLE. Cancer prevalence was the highest in the first 5-10 years of lupus. Breast cancer was the most common malignancy (n= 11) followed by gastrointestinal tumors (n= 9), cervix cancer and hematologic malignancies (n= 5 for both), bronchial cancer (n= 4), bladder, skin, and ovarian cancer (n= 1 for each). Standardized incidence ratio was the highest for non-Hodgkin lymphoma (standardized incidence ratio [SIR] 3.5, 95%CI 0.4-12.5) and cervix cancer (SIR 1.7, 95%CI 0.6-4.1). Although 76% of patients with cancer received immune-suppressive therapy besides corticosteroids, no direct correlation could be confirmed between therapy and malignancy. Out of the 164 patients that expired during the study period, 18 were cancer-related. As such the cancer-associated mortality was 11% (18/164). This peaked during the last 4 years of the study period (8/24, 33%). Lupus patients are at high risk for particular types of malignant disorders, highlighting the importance of screening measures and focused patient examination.

Keywords: lupus; cancer; malignancy; lymphoma

Document Type: Research article

DOI: 10.1196/annals.1422.008

Affiliations: 1: Third Department of Medicine, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary 2: Department of Oncology, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary 3: Department of Clinical Biochemistry and Molecular Pathology, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$50.39 plus tax Refund Policy

Occurrence of Malignancies in Hungarian Patients with Systemic Lupus Erythematosus